Methods for diagnosing and treating neuroendocrine cancer

1. A method for affecting the proliferation of a neuroendocrine tumor cell comprising contacting a neuroendocrine tumor cell, wherein the neuroendocrine tumor cell comprises a small cell lung, ovarian or pancreatic tumor cell, with an effective amount of an antagonist of an NMDA glutamate receptor that selectively inhibits an NMDA glutamate type 2 receptor, and further wherein said antagonist inhibits or decreases the expression of the NMDA glutamate type 2 receptor or antagonizes the glutamate site, glycine site, polyamine site or channel pore of the NMDA glutamate type 2 receptor and inhibits or decreases NMDA glutamate type 2 receptor activity; and measuring the proliferation of the neuroendocrine tumor cell, wherein decreased proliferation results from the inhibition of the NMDA glutamate type 2 receptor.

2. A method for treating a neuroendocrine cancer in a subject comprising administering to a subject having a neuroendocrine cancer, wherein the neuroendocrine cancer comprises small cell lung cancer, ovarian cancer, or pancreatic cancer, an effective amount of an antagonist of a NMDA glutamate receptor that inhibits or decreases the expression of NMDA glutamate type 2 receptor or antagonizes the glutamate site, glycine site, polyamine site or channel pore of NMDA glutamate type 2 receptor and inhibits or decreases NMDA glutamate type 2 receptor activity, and measuring the proliferation of neuroendocrine cancer tumor cells in the subject, wherein the neuroendocrine tumor cells are selected from the group consisting of small cell lung cancer tumor cells, ovarian cancer tumor cells, or pancreatic cancer tumor cells, and wherein decreased proliferation of the neuroendocrine cancer tumor cells results from inhibition of the NMDA glutamate type 2 receptor and treats the neuroendocrine cancer in the subject.